Skip to main content
SpringerLink
Log in

Lipids in 2012

HDL cholesterol studies—more of the same?

  • Year in Review
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

Studies published in 2012 in the field of HDL research have provided further evidence suggesting that a low HDL-cholesterol level, in the absence of related lipid or nonlipid risk factors, is not associated with increased risk of coronary heart disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Mechanisms linking HDL to cardiovascular disease.

References

  1. Després, J. P., Lemieux, I., Dagenais, G. R., Cantin, B. & Lamarche, B. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 153, 263–272 (2000).

    Article  Google Scholar 

  2. Brewer, H. B. Jr. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J. Clin. Endocrinol. Metab. 96, 1246–1257 (2011).

    Article  CAS  Google Scholar 

  3. Barter, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53, 1755–1766 (2012).

    Article  CAS  Google Scholar 

  4. Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007).

    Article  CAS  Google Scholar 

  5. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).

    Article  CAS  Google Scholar 

  6. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).

    Article  CAS  Google Scholar 

  7. Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572–580 (2012).

    Article  CAS  Google Scholar 

  8. Mackey, R. H. et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 60, 508–516 (2012).

    Article  CAS  Google Scholar 

  9. Parish, S. et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 125, 2469–2478 (2012).

    Article  CAS  Google Scholar 

  10. Arsenault, B. J. & Després, J. P. Lipids: HDL cholesterol is not HDL—don't judge the book by its cover. Nat. Rev. Cardiol. 9, 557–558 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Pavilion Marguerite-D'Youville, 4th Floor, 2725 chemin Ste-Foy, QC G1V 4G5, Québec, Canada

    Jean-Pierre Després

Authors
  1. Jean-Pierre Després
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

J.-P. Després has received honoraria from Abbott, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer Canada, and has acted as a consultant for Novartis, Sanofi, Theratechnologies, and Torrent Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Després, JP. HDL cholesterol studies—more of the same?. Nat Rev Cardiol 10, 70–72 (2013). https://doi.org/10.1038/nrcardio.2012.182

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2012.182

  • Springer Nature Limited

This article is cited by

Search

Navigation